Ray Ga Ming Li's Contributor Page
|
Ray is currently a senior at Northeastern University majoring in Business Administration and Economics with prior experience as a Portfolio Management associate intern with the Active Equity Products team at State Street Global Advisors. Ray recently joined G2 Capital Advisors as an Investment Banking spring analyst within the M&A division.
Gutenberg Company Assignments: Foot Locker (NYSE:FL), Square Inc (NYSE:SQ), Phillips 66 (NYSE:PSX) and Jazz Pharma PLC (NASDAQ:JAZZ) Contributor Type: Intern, Senior Research Associate. Prospective employers may contact Ray to discuss opportunities using the email link below. |
Ray's Models
Source: Gutenberg Research
|
Foot Locker Inc (NYSE:FL)
Latest Update: November 25, 2016 Model Tier: Tier 1, Consensus-based model. Financial Modeling Approach: This model uses estimates for store counts, square footage, and sales per square foot to forecast revenue for the Athletic Store Division, and applies growth rates with adjustments for historic seasonality to estimate earnings for the Direct-to-Customer Division. 
| ||
Source: Square Inc
|
Square Inc (NYSE:SQ)
Latest Update: November 9, 2016 Model Tier: Tier 2, Consensus-based model. Financial Modeling Approach: This model projects future earnings based on Gross Payment Volume (GPV) estimates and segment margin forecasts.
| ||
Source: Gutenberg Research
|
Jazz Pharma PLC (NASDAQ:JAZZ)
Latest Update: July 7, 2016. Model Summary: This model predicts revenue by drug, and then uses ratio analysis to build the income statement and project future earnings.
| ||
|
Phillips 66 (NYSE:PSX)
Latest Update: May 24, 2016. Model Summary: This model breaks down Phillips' operations between Midstream, Chemicals, Refining, and Marketing operations and uses various statistics and assumptions to project future earnings. |
| ||
Ray's Articles
Square Posts Strong Third Quarter Results
Square Inc (NYSE:SQ) reported strong third quarter results today and increased full-year guidance for revenue and EBITDA. The company announced third quarter Gross Payment Volume (GPV) of $13.2B up 39% Year-over-Year (YoY), adjusted revenue of $178 up 51% YoY, adjusted EBITDA of $12M up from a loss of $16M last year, and an adjusted EBITDA margin of 7%. Management attributed the improvement this quarter to strength in the cash advance lending business which was up 70% YoY, and growth in GPV from large sellers (those with more than one retail store), which was up 55% YoY. Click to continue reading
Square Inc (NYSE:SQ) reported strong third quarter results today and increased full-year guidance for revenue and EBITDA. The company announced third quarter Gross Payment Volume (GPV) of $13.2B up 39% Year-over-Year (YoY), adjusted revenue of $178 up 51% YoY, adjusted EBITDA of $12M up from a loss of $16M last year, and an adjusted EBITDA margin of 7%. Management attributed the improvement this quarter to strength in the cash advance lending business which was up 70% YoY, and growth in GPV from large sellers (those with more than one retail store), which was up 55% YoY. Click to continue reading
Jazz Pharmaceuticals 2Q16 Outlook
The key highlights from 1Q16 earnings call are in three primary drugs Xyrem, Erwinaze and Deifetelio and how the company plans to expand them going into FY16. The main highlight is the in line FDA approval on Defitelio on March 30 to allow the drug to be commercially launched in the United States. While, this is a clear positive with increasing concerns in the recent market trends, investors should expect little changes going into 2Q16. Click to continue reading
The key highlights from 1Q16 earnings call are in three primary drugs Xyrem, Erwinaze and Deifetelio and how the company plans to expand them going into FY16. The main highlight is the in line FDA approval on Defitelio on March 30 to allow the drug to be commercially launched in the United States. While, this is a clear positive with increasing concerns in the recent market trends, investors should expect little changes going into 2Q16. Click to continue reading